A Phase 2 interventional study of Placebo and Brivaracetam in Epilepsy, Focal, sponsored by UCB Pharma. Completed at 57 sites in 9 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-13.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Epilepsies, Partial by UCB S.A. — none open to participants now, none under way, none of them phase 3. Epilepsies, Partial · UCB S.A..
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2005, is one of 6 in phase 2, and was the 11th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 29 studies in Epilepsies, Partial by UCB S.A. is open now. The open studies under Epilepsies, Partial, anywhere →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 1998; this study’s year is marked. 5 started in 2005.
This study's enrollment of 157 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 154 across the 25 interventional studies, 576 across the 3 observational. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Epilepsies, Partial by UCB S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Matching placebo tablets administered twice a day
Other: Placebo
Brivaracetam 50 mg/day, 25 mg administered twice a day
Drug: Brivaracetam
Brivaracetam 150 mg/day, 75 mg administered twice a day
Drug: Brivaracetam
Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Partial onset seizure frequency (Type I) per week over the 7-week maintenance period
Partial onset seizure frequency (Type I) per week over the 7-week maintenance period
Time frame: 7-week maintenance period
Seizure frequency per week for all seizures (types I+II+III) over the 7-week Maintenance period
Time frame: During the Maintenance period (approximately 7 weeks)
Percentage of reduction from Baseline in seizure frequency per week for partial onset seizures (type I) over the 7-week Maintenance period
Time frame: During the Maintenance period (approximately 7 weeks)
Percentage of reduction from Baseline in seizure frequency per week for all seizures (types I+II+III) over the 7-week Maintenance period
Time frame: During the Maintenance period (approximately 7 weeks)
Responder rate in partial onset seizures (type I) over the 7-week Maintenance period
A responder was defined as a subject with a ≥ 50% reduction in seizure frequency per week from the Baseline period to the Maintenance period.
Time frame: During the Maintenance period (approximately 7 weeks)
Response to treatment in partial onset seizures (type I) over the 7-week Maintenance period
The percentage reduction from Baseline in partial seizure frequency per week over the Maintenance period was grouped in 5 categories: \< -25%, -25% to \< 25%, 25% to \< 75%, 75% to ≤ 100%, and 100%.
Time frame: During the Maintenance period (approximately 7 weeks)
Percentage of seizure-free subjects over the 7-week Maintenance period
Time frame: During the Maintenance period (approximately 7 weeks)
Percentage of seizure-free days per 4 weeks over Baseline and Maintenance periods
Time frame: Baseline through Maintenance period (approximately 11 weeks)
Time to N-th seizure in the Maintenance period
Time frame: During the Maintenance period (approximately 7 weeks)
The record gives a start of May 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam